8 completed, 1 terminated. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
Follow Childhood Mixed Glioma: new trials by email Literature Review of Childhood Mixed Glioma trials Research Report on Childhood Mixed Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Anaplastic Astrocytoma, Brain Stem Glioma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 66 | 2012-02-01 | 2019-08-13 |
| Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Diagnostic Laboratory Biomarker Analysis, Pharmacological Study, Sunitinib Malate - Childhood Cerebellar Anaplastic Astrocytoma, Childhood Cerebral Anaplastic Astrocytoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2012-01-01 | 2015-08-27 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 129 | 2010-03-01 | 2014-11-05 |
| Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-02-01 | 2013-05-03 |
| Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma vorinostat, bortezomib, pharmacological study - Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2009-08-01 | 2013-07-02 |
| ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors veliparib, temozolomide, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 31 | 2009-07-01 | 2014-07-09 |
| Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors lenalidomide, perfusion-weighted magnetic resonance imaging, diffusion-weighted magnetic resonance imaging - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2004-11-01 | 2013-09-30 |
| Cilengitide in Treating Children With Refractory Primary Brain Tumors cilengitide, laboratory biomarker analysis - Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2003-07-01 | 2013-09-30 |
| Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors O6-benzylguanine, temozolomide, filgrastim - Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 72 | 2002-10-01 | 2013-09-30 |
Astrocytoma (9) · Familial ependymoma (8) · Oligodendroglioma (8) · Choroid Plexus Neoplasms (7) · Medulloblastoma (7) · Optic Nerve Glioma (7) · Rhabdoid Tumor (4) · Spinal Cord Neoplasms (3) · Burkitt Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Lymphoma, Large-Cell, Anaplastic (2) · Recurrence (2) · Adenoma, Acidophil (1) · Adenoma, Basophil (1) · Adenoma, Chromophobe (1)
Glioma (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Glandular and Epithelial (9) · Neoplasms, Nerve Tissue (9) · Neoplasms, Neuroepithelial (9) · Neuroectodermal Tumors (9) · Brain Diseases (7) · Brain Neoplasms (7) · Central Nervous System Diseases (7) · Central Nervous System Neoplasms (7) · Cerebral Ventricle Neoplasms (7) · Cranial Nerve Diseases (7) · Cranial Nerve Neoplasms (7)
Temozolomide (4) · Vorinostat (2) · veliparib (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Bortezomib (1) · Calcium Dobesilate (1) · Cilengitide (1) · Dexamethasone (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Lenalidomide (1) · O(6)-benzylguanine (1) · Radiotherapy, Conformal (1) · Radiotherapy, Intensity-Modulated (1) · Sunitinib (1)
National Cancer Institute (NCI) (9)
United States (9) · Canada (3) · Australia (1)
Amar Gajjar (1) · Cynthia Wetmore (1) · Jack Su (1) · Jodi Muscal (1) · Katherine Warren (1) · Najat Daw (1) · Tobey MacDonald (1) · Trent Hummel (1)
PMID 23554030, PMID 27109549, PMID 32009149, PMID 32623479, PMID 33571520, PMID 33852135
U01CA081457 (5), U01CA097452 (3), U10CA098543 (1), UM1CA081457 (1)